Topics
Glioblastoma | Treatment | Immunotherapy | Immune Checkpoint Inhibitors
Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Immune Checkpoint Inhibitors
Wang
H, Yang J, Li X, Zhao H.
Current
state of immune checkpoints therapy for
glioblastoma.
Heliyon.
2024 Jan 13;10(2):e24729. doi:
10.1016/j.heliyon.2024.e24729.
PMID:
38298707. Review. ˍ
Ser MH, Webb MJ, Sener U, Campian JL.
Immune
Checkpoint Inhibitors and Glioblastoma: A Review on Current State
and Future Directions.
J
Immunother Precis Oncol. 2024 May 2;7(2):97-110. doi:
10.36401/JIPO-23-34. PMID:
38721406.
Review. ˍ
Wu J, Wang N.
Current
progress of anti-PD-1/PDL1 immunotherapy for glioblastoma
(Review).
Mol
Med Rep. 2024 Sep 30;30(6):221. doi:
10.3892/mmr.2024.13344. PMID:
39364736. Review. ˍ
Rodriguez SMB, Tataranu LG, Kamel A, Turliuc S, Rizea RE, Dricu
A.
Glioblastoma
and Immune Checkpoint Inhibitors: A Glance at Available Treatment
Options and Future Directions.
Int
J Mol Sci. 2024 Oct 7;25(19):10765. doi:
10.3390/ijms251910765. PMID:
39409094. Review. ˍ
Du R, Zhang J, Lukas RV, Tripathi S, Ahrendsen JT, Curran MA,
Dmello C, Zhang P, Stupp R, Rao G, Heimberger AB.
Is
modulation of immune checkpoints on glioblastoma-infiltrating
myeloid cells a viable therapeutic strategy?
Neuro
Oncol. 2024 Oct 19:noae193. doi:
10.1093/neuonc/noae193. PMID:
39427326. Review. ˍ
Schonfeld E, Choi J, Tran A, Kim LH, Lim M.
The
landscape of immune checkpoint inhibitor clinical trials in
glioblastoma: A systematic review.
Neurooncol
Adv. 2024 Nov 12;6(1):vdae174. doi:
10.1093/noajnl/vdae174. PMID:
39534539. Review. ˍ
Badani A, Ozair A, Khasraw M, Woodworth GF, Tiwari P, Ahluwalia
MS, Mansouri A.
Immune checkpoint
inhibitors for glioblastoma: emerging science, clinical
advances, and future directions.
J
Neurooncol. 2024 Nov 21. doi:
10.1007/s11060-024-04881-2. PMID:
39570554. Review˰ ˍ